Elizabeth Dudnik

BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors

Elizabeth Dudnik, Nir Peled, Hovav Nechushtan et al. · Journal of Thoracic Oncology · 2018 · 219 citations · Full text

Tumor Mutational Burden, Death Ligand 1, Medicine +9

Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases

Elizabeth Dudnik, Shlomit Yust‐Katz, Hovav Nechushtan et al. · Lung Cancer · 2016 · 135 citations

Neuro-oncology, Cns Metastases, Intracranial Pressure +8

Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study

Jair Bar, Gal Markel, Teodor Gottfried et al. · European Journal of Cancer · 2019 · 102 citations

Thrombosis, Vascular Disease, Vasculitis +14

Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data

Elizabeth Dudnik, Mor Moskovitz, Sameh Daher et al. · Lung Cancer · 2017 · 101 citations

Real-life Data, Medicine, Cancer Management +7

ALK-Rearranged Non–Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism

Alona Zer, Mor Moskovitz, David Hwang et al. · Clinical Lung Cancer · 2016 · 98 citations